Biomarkers for Drug-Induced Kidney Injury Receive Boost From EMA, FDA

Drug Industry Daily
The European Medicines Agency has lent its support to an initiative to qualify biomarkers that can provide an early warning on an investigational compound’s risks of causing drug-induced kidney injuries, an endorsement that researchers say is necessary to move to the next phase of development.

To View This Article:


Subscribe To Drug Industry Daily